{"task_id": "ff188540dccc7cbc", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 241/464)", "text": "; urgent\nintervention indicated\n230\nOral Mucositis\n\n--- Page 252 ---\nMANAGEMENT\nCRYOTHERAPY\nsucking on ice chips during che\nmotherapy is a reasonable preventative strategy for\npatients on 5 fluorouracil, edatrexate, or high dose\nmelphalan\nORAL HYGIENE\nsoft tooth brush, flossing, mouth\nrinses q4h (0.9% saline, baking soda, or salt and\nbaking soda solution by mixing one teaspoon of\nbaking soda and half teaspoon of salt in 1/L of\nwater), denture care (if applicable)\nDOSE ADJUSTMENTS\ndose reduction or treatment\ntermination may be considered in severe cases\nSUPPORTIVE MEASURES\nensure adequate hydra\ntion and monitor nutritional intake. Assess patients\nfor diarrhea as well. Providing optimal pain control is\nkey\nMANAGEMENT (CONT\u2019D)\n\u0002\nTOPICAL ANALGESIA\n\u0002\nMAGIC/MIRACLE MOUTHWASH\ngenerally includes\nlidocaine for pain control. For a 100 mL solution,\nmix hydrocortisone 25 mg, glycerin 95% 2 mL,\nnormal saline 52 mL, lidocaine 2% 25 mL, and\nnystatin 2083,300 IU or 20.833 mL. Use 10 mL\nsquish and spit q4h q6h\n\u0002\nMORPHINE SULFATE MOUTHWASH\n2 mg/mL in\n15 mL of water, swish and spit, q4h to q6h\n\u0002\nLIDOCAINE VISCOUS 2%\n10 mL, swish and spit,\nq4h PRN\n\u0002\nSYSTEMIC OPIOIDS\nmorphine 5 mg IV q4h PRN or\n10 mg PO q4h PRN, titrating up as needed\n\u0002\nINFECTIONS\noral candidiasis (nystatin 500,000 IU\nswish and swallow QID, clotrimazole troches, or\nfluconazole), HSV infections (acyclovir or valacy\nclovir after cultures taken)\nChemotherapy-Induced Diarrhea\nJCO 2004 22:14\nPATHOPHYSIOLOGY\nRISK FACTORS FOR CHEMOTHERAPY INDUCED\nDIARRHEA\n\u0002\nCHEMOTHERAPY\n5 fluorouracil, capecitabine, irino\ntecan (active metabolite SN 30), cisplatin, docetaxel,\npaclitaxel, doxorubicin, cyclophosphamide, metho\ntrexate, cytosine arabinoside, and topotecan\n\u0002\nTARGETED AGENTS\nimatinib, erlotinib, sunitinib,\nsorafenib\nNCI CTC GRADING V4.0\nGrade\nChemotherapy Induced Diarrhea\n1\nIncrease of <4 stools per day over\nbaseline; mild increase in ostomy\noutput compared to baseline\n2\nIncrease of 4 6 stools per day over\nbaseline; moderate increase in ostomy\noutput compared to baseline\n3\nIncrease of \u00057 stools per day over baseline;\nincontinence; hospitalization; severe\nincrease in ostomy output compared to\nbaseline; limiting self care ADL\n4\nLife threatening consequences; urgent\nintervention indicated\nMANAGEMENT\nDOSE ADJUSTMENTS\ndose reduction or treatment\ntermination may be considered in severe cases\nFIRST LINE\nloperamide 4 mg PO, followed by 2 mg\nevery 2 h (or 4 mg every 4 h) until 12 h has elapsed\nwithout any diarrhea\nSECOND\nLINE\noctreotide\n100 150\nmg\nSC\nas\nneeded. Octreotide is a somatostatin analogue that\ndecreases both intestinal transit time and fluid secre\ntion into the small intestine\nNOTE\nensure adequate hydration and assess other\nrelated symptoms such as oral mucositis, nausea, and\nvomiting. Remember to stop all laxatives\nChemotherapy-Induced Diarrhea\n231", "text_length": 2834, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 241/464)", "type": "chunk", "chunk_index": 240, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.578425", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.579195", "status": "complete", "chunks_added": 2}